"Amid a threat of towering US tariffs, Swiss pharmaceutical giant Novartis is seeking ways to enable Americans to pay less for their medicines, its chief said in an interview published Saturday. Vasant Narasimhan told the Swiss daily Neue Zurcher Zeitung (NZZ) that his company was "working to eliminate the price gap between the US and other industrialised countries". "We are working with the government and trying to find constructive solutions so that Americans pay less for their medicines," he told the Swiss daily."
"US President Donald Trump has threatened to hit the entire sector with tariffs of as much as 250 percent if drug prices do not drop. Narasimhan suggested it made sense to bring down US prices. "It is a fact that American patients pay for a large part of the innovations," he acknowledged to the NZZ, insisting that "countries outside the US will have to contribute a larger share in the future"."
"Pharmaceutical companies are meanwhile facing massive pressure from the Trump administration to move production to the United States. Novartis already announced in April that it plans to invest $23 billion in the United States over five years. The goal was "to manufacture the most important products for the American market locally", he said, adding that it would "probably take three to four years to get there"."
Novartis is pursuing measures to reduce the price gap that makes US patients pay more for medicines and is cooperating with the government to lower American drug costs. The company acknowledges that US patients fund much of pharmaceutical innovation and says other countries will need to bear a larger share in future. Facing threats of tariffs up to 250 percent, Novartis plans to shift production toward the United States, including local manufacture of key products. The company announced a $23 billion US investment over five years, expects major changes within two years and complete shifts in three to four years.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]